Posted by Michael Wonder on 08 Dec 2016
Agenda for 14 December 2016 TC meeting
8 December 2016 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of dalbavancin hydrochloride (Xydalba), cabozantinib maleate (Cabometyx), insulin degludec with liraglutide (Xultophy), sitagliptin phosphate monohydrate (Januvia) and sitagliptin phosphate monohydrate with metformin hydrochloride (Janumet).
